Associations of serum neuromarkers with clinical features of Parkinson’s disease

Nikitina MA, Koroleva ES, Brazovskaya NG, Boiko AS, Levchuk LA, Ivanova SA, Alifirova VM. Associations of serum neuromarkers with clinical features of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):145‑152. (In Russ.)
https://doi.org/10.17116/jnevro2024124041145

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the clinical and laboratory correlation of biomarkers with anti- and pro-apoptotic activity with the severity of motor and non-motor symptoms depending on the progression rate of Parkinson’s disease (PD).

MATERIAL AND METHODS

A wide range of non-motor symptoms (emotional-affective, cognitive, psychotic and behavioral disorders, fatigue, sleep disorders and autonomic disorders) was evaluated using validated scales and a number of serum neuromarkers responsible for neuroplasticity and neuronal survival processes (BDNF, PDGF, cathepsin D) in 71 patients with PD (mean age 65 (55; 70) years, disease duration 7 (4; 9) years, age of onset 57 (49; 62) years).

RESULTS

The concentration of biomarkers (BDNF, PDGF and cathepsin D) was the lowest in the group of patients with a rapid PD progression rate (p<0.001, p=0.001 and p=0.031, respectively), the severity of motor and most non—motor symptoms was higher (p=0.023 and p=0.001, respectively) compared to middle and slow progression rate. There were correlations between BDNF concentration and the severity of depression (r=–0.63, p<0.001), apathy (r=–0.48, p<0.001), impulsive behavioral disorders (r=0.500, p<0.001), level of cognitive functions (r=0.54, p<0.001), motor symptoms (r=–0.43, p<0.001); between PDGF level and the severity of motor manifestations of PD (r=–0.30, p=0.011), depression (r=–0.70, p<0.001), apathy (r=–0.460, p<0.001), the degree of severity of behavioral disorders (r=0.742, p<0.001). No significant correlations were observed between the level of cathepsin D and the severity of clinical manifestations of PD, which indicates the connection of cathepsin D with the general pathogenesis of PD.

CONCLUSION

The possibility of using serum proteins of the neurotrophin subfamily and the protein associated with autophagy, cathepsin D, as biomarkers that determine the prognosis of PD, is considered.

Keywords:

Parkinson’s disease

neurodegeneration

neurotrophins

autophagy

rate of progression

brain-derived neurotrophic factor

platelet-derived growth factor

cathepsin D

Authors:

Nikitina M.A.

Siberian State Medical University

ORCID: 0000-0002-2614-207X

Koroleva E.S.

Siberian State Medical University

SPIN RSCI: 6009-8113
Scopus AuthorID: 56299905400
ORCID: 0000-0003-1911-166X

Brazovskaya N.G.

Siberian State Medical University

ORCID: 0000-0002-0706-9735

Boiko A.S.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0002-2955-9057

Levchuk L.A.

Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences

ORCID: 0000-0003-1982-8492

Ivanova S.A.

Siberian State Medical University;
Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences

ORCID: 0000-0001-7078-323X

Alifirova V.M.

Siberian State Medical University

SPIN RSCI: 3824-1016
Scopus AuthorID: 6507431329
ORCID: 0000-0002-4140-3223

Received:

28.09.2023

Accepted:

01.10.2023

Close metadata

References:

Kumar A, Patil S, Singh VK, et al. Assessment of Non-Motor Symptoms of Parkinson’s Disease and Their Impact on the Quality of Life: An Observatiobnal Study. Ann Indian Acad Neurol. 2022;25(5):909-915. https://doi.org/10.4103/aian.aian_647_21
Illarioshkin SN. Parkinson’s disease in the context of the COVID-19 pandemic. Nervous diseases. 2021;4:11-19. (In Russ.). https://doi.org/10.24412/2226-0757-2021-12372
Nikitina MA, Zhukova NG, Bragina EYu, et al. The heterogeneity of non-motor symptoms in patients with Parkinson’s disease in Tomsk region. Yakut Medical Journal. 2019;3(67):70-74. (In Russ.). https://doi.org/10.25789/YMJ.2019.67.20
Funa K, Sasahara M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J Neuroimmune Pharmacol. 2014;9(2):168-181. https://doi.org/10.1007/s11481-013-9479-z
Sidibe DK, Kulkarni VV, Dong A, et al. Brain-derived neurotrophic factor stimulates the retrograde pathway for axonal autophagy. J Biol Chem. 2022;298(12):102673. https://doi.org/10.1016/j.jbc.2022.102673
Paul G, Zachrisson O, Varrone A, et al. Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients. J Clin Invest. 2015;125(3):1339-1346. https://doi.org/10.1172/JCI79635
Levchuk LA, Meeder EMG, Roschina OV, et al. Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. Front Psychiatry. 2020;11:296. https://doi.org/10.3389/fpsyt.2020.00296
Rezaee Z, Marandi SM, Alaei H. Molecular Mechanisms of Exercise in Brain Disorders: a Focus on the Function of Brain-Derived Neurotrophic Factor-a Narrative Review. Neurotox Res. 2022;40(4):1115-1124. https://doi.org/10.1007/s12640-022-00527-1.
Koroleva ES, Tolmachev IV, Alifirova VM, et al. Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. Brain Sci. 2020;10(9):623. https://doi.org/10.3390/brainsci10090623
Vidoni C, Follo C, Savino M, et al. The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders. Med Res Rev. 2016;36(5):845-870. https://doi.org/10.1002/med.21394
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-601.
Rosinskaia AV, Vasenina EE, Khaybullin TN, et al. Rate of progression of Parkinson’s disease with early and delayed prescription of levodopa preparations. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6-2):77-81. (In Russ.). https://doi.org/10.17116/jnevro201811806277
Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders. 2007;22(1):41-47. https://doi.org/10.1002/mds.21198
Beck C, Gable R. Postpartum Depression Screening Scale: Development and Psychometric Testing. Nursing Research. 2000;49(5):272-282. https://doi.org/10.1097/00006199-200009000-00006
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatria Scandinavica. 1983;67(6):361-370.
Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences. 1992;4(2):134-139.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;(14):540-545.
Chappell P, Feltner DE, Makumi C, et al. Initial Validity and Reliability Data on the Columbia—Suicide Severity Rating Scale. American Journal of Psychiatry. 2012;169(6):662-663. https://doi.org/10.1176/appi.ajp.2012.12010123
Evans AH, Okai D, Weintraub A, et al. Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee. Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: Critique and recommendations. Mov Disord. 2019;34(6):791-798. https://doi.org/10.1002/mds.27689
Fedorova NV, Yablonskaya AYu. A scale for assessing autonomic disorders in patients with Parkinson’s disease. Methodological development. GOU DPO RMAPO. M. 2011;2-30. (In Russ.).
Dadu A, Satone V, Kaur R, et al. Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts. NPJ Parkinsons Dis. 2022;8(1):172. https://doi.org/10.1038/s41531-022-00439-z
Weintraub D, Mamikonyan E. Impulse Control Disorders in Parkinson’s Disease. Am J Psychiatry. 2019;176(1):5-11. https://doi.org/10.1176/appi.ajp.2018.18040465
Pan W, Banks WA, Fasold MB, et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37(12):1553-1561. https://doi.org/10.1016/s0028-3908(98)00141-5
Klein AB, Williamson R, Santini MA, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14(3):347-353. https://doi.org/10.1017/S1461145710000738
Chung CC, Huang PH, Chan L, et al. Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance-Related Motor Symptoms in Patients with Parkinson’s Disease. Diagnostics (Basel). 2020;10(9):684. https://doi.org/10.3390/diagnostics10090684
De Pablo-Fernández E, Lees AJ, Holton JL, et al. Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurol. 2019;76(4):470-479. https://doi.org/10.1001/jamaneurol.2018.4377
Kang J, Kim JW, Heo H, et al. Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease. Clin Transl Sci. 2021;14(2):606-616. https://doi.org/10.1111/cts.12920
Kotagal V. Is PIGD a legitimate motor subtype in Parkinson disease? Ann Clin Transl Neurol. 2016;3(6):473-477. https://doi.org/10.1002/acn3.312
Olson M, Lockhart TE, Lieberman A. Motor Learning Deficits in Parkinson’s Disease (PD) and Their Effect on Training Response in Gait and Balance: A Narrative Review. Front Neurol. 2019;10:62. https://doi.org/10.3389/fneur.2019.00062
Wang Y, Liu H, Du XD, et al. Association of low serum BDNF with depression in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;41:73-78. https://doi.org/10.1016/j.parkreldis.2017.05.012
Wang Y, Bai LP, Liu W, et al. Altered BDNF levels are associated with cognitive impairment in Parkinson’s disease patients with depression. Parkinsonism Relat Disord. 2022;103:122-128. https://doi.org/10.1016/j.parkreldis.2022.08.020